<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625518</url>
  </required_header>
  <id_info>
    <org_study_id>0114-18</org_study_id>
    <nct_id>NCT03625518</nct_id>
  </id_info>
  <brief_title>Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes</brief_title>
  <official_title>Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      to compare methods of induction of labor in fetal growth restriction and its effect on
      maternal and neonatal outcome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intra uterine growth restriction (FGR) is a condition in which the fetus does not realize its
      growth potential in uterus. The excepted definitions of this condition are fetal weight
      estimation below the 10th percentile per gestational week. Severe growth restriction is
      defined as estimated weight below the 3rd percentile. It is well known that fetuses which are
      growth restricted are subjected to a higher degree of complications during pregnancy and
      delivery such as fetal distress, hypoxic damage, intra uterine fetal demise and complications
      in the neonatal period including prolonged NICU hospitalization, cerebral palsy, hypoxic
      ischemic encephalopathy and also long term affects such as neuro developmental complications.

      Common practice in managing these cases is induction of labor at term around 37 weeks of
      gestations to prevent these complications as it established that during this time there is a
      substantial rise in pregnancy complications including fetal demise.

      There are no clear guide lines how to induce labor in such cases and it is not known what is
      the safest and the most effective way to induce labor in these cases. Prior studies have
      found the rate of successful vaginal birth in these cases vary between 50 and 80%. There are
      a number of methods of labor induction and delivery available including the use of vaginal
      prostaglandins (PGE2) for cervical ripening, intracervical balloon catheter or planned
      cesarean. In most cases when aiming for vaginal delivery the choice is between ripening of
      the cervix with balloon catheter in combination with Pitocin or ripening with prostaglandins.
      It is not known which method is safer and more successful in growth restricted fetuses.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mode of delivery</measure>
    <time_frame>immediate</time_frame>
    <description>vaginal delivery, instrumental delivery or cesarean delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>composite neonatal outcome</measure>
    <time_frame>3 months after delivery</time_frame>
    <description>apgar score at birth, umilical cord blood gases, neonatal intensive care unit hospitalization,Intra ventricular hemorrhage, periventricular leukomalacia, meconium aspiration syndrome, sepsis, convulsion, perinatal death, need for hypothermia treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Fetal Growth Retardation</condition>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <arm_group>
    <arm_group_label>prostaglandins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vaginal prostaglandins insertion (PGE2) for cervical ripening and induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intracervical balloon catheter with pitocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>insertion of intra cervical balloon catheter combined with intravenous pitocin for ripening and induction of labor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prostaglandins E2</intervention_name>
    <description>insertion of vaginal PGE2 for up to 30 hours, up to two attempts for cervical ripening and induction</description>
    <arm_group_label>prostaglandins</arm_group_label>
    <other_name>dinoprostone slow release pessary</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intracervical balloon catheter combined with pitocin</intervention_name>
    <description>insertion of Foley catheter intra cervical and inflating the balloon with 50-60 cc of saline, with IV pitocin according to hospital protocol</description>
    <arm_group_label>intracervical balloon catheter with pitocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  singleton pregnancy

          -  fetal growth restriction defined as estimated fetal weight between the 3rd and 10th
             percentile per gestational age and are intended to deliver vaginally

          -  Gestational age between 36 and 42 weeks

          -  No known fetal anomalies

        Exclusion Criteria:

          -  Fetal estimated weight below the 3rd percentile

          -  Known fetal anomalies

          -  Contraindications for vaginal delivery: breech presentation, abnormal Doppler flow
             velocimetry of fetal ductus venosus.

          -  Oligohydramnios defined as amniotic fluid index below 5 cm

          -  Contraindication to the use of prostaglandins

          -  Fetal distress requiring emergent cesarean section

          -  All other condition preventing vaginal delivery as decided by a senior physician
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ayelet Dangot, MD</last_name>
    <phone>972524262658</phone>
    <email>adangot@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lis Maternity Hospital, Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Kuperminc, MD</last_name>
      <phone>97236925633</phone>
    </contact>
    <contact_backup>
      <last_name>Ayelet Dangot, MD</last_name>
      <phone>97236925633</phone>
    </contact_backup>
    <investigator>
      <last_name>Michael Kuperminc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayelet Dangot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Figueras F, Gratac√≥s E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther. 2014;36(2):86-98. doi: 10.1159/000357592. Epub 2014 Jan 23. Review.</citation>
    <PMID>24457811</PMID>
  </reference>
  <reference>
    <citation>Baschat AA. Fetal growth restriction - from observation to intervention. J Perinat Med. 2010 May;38(3):239-46. doi: 10.1515/jpm.2010.041. Review.</citation>
    <PMID>20205623</PMID>
  </reference>
  <reference>
    <citation>Walker DM, Marlow N. Neurocognitive outcome following fetal growth restriction. Arch Dis Child Fetal Neonatal Ed. 2008 Jul;93(4):F322-5. doi: 10.1136/adc.2007.120485. Epub 2008 Apr 1. Review.</citation>
    <PMID>18381841</PMID>
  </reference>
  <reference>
    <citation>Boers KE, Vijgen SM, Bijlenga D, van der Post JA, Bekedam DJ, Kwee A, van der Salm PC, van Pampus MG, Spaanderman ME, de Boer K, Duvekot JJ, Bremer HA, Hasaart TH, Delemarre FM, Bloemenkamp KW, van Meir CA, Willekes C, Wijnen EJ, Rijken M, le Cessie S, Roumen FJ, Thornton JG, van Lith JM, Mol BW, Scherjon SA; DIGITAT study group. Induction versus expectant monitoring for intrauterine growth restriction at term: randomised equivalence trial (DIGITAT). BMJ. 2010 Dec 21;341:c7087. doi: 10.1136/bmj.c7087.</citation>
    <PMID>21177352</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists. ACOG Practice bulletin no. 134: fetal growth restriction. Obstet Gynecol. 2013 May;121(5):1122-33. doi: 10.1097/01.AOG.0000429658.85846.f9.</citation>
    <PMID>23635765</PMID>
  </reference>
  <reference>
    <citation>Horowitz KM, Feldman D. Fetal growth restriction: risk factors for unplanned primary cesarean delivery. J Matern Fetal Neonatal Med. 2015;28(18):2131-4. doi: 10.3109/14767058.2014.980807. Epub 2014 Nov 14.</citation>
    <PMID>25354283</PMID>
  </reference>
  <reference>
    <citation>Maslovitz S, Shenhav M, Levin I, Almog B, Ochshorn Y, Kupferminc M, Many A. Outcome of induced deliveries in growth-restricted fetuses: second thoughts about the vaginal option. Arch Gynecol Obstet. 2009 Feb;279(2):139-43. doi: 10.1007/s00404-008-0685-5. Epub 2008 May 28.</citation>
    <PMID>18506461</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

